Systemic sclerosis & Raynaud's
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease
Authors' conclusion
Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time.
Study context
- Population
- International experts classifying actual SSc-ILD patient profiles44 (53%) experts completed
- Participants
- 83 participants
- Outcome
- Consensus (≥75% of experts agreeing) on classifying SSc-ILD profiles by severity, risk of progression and progressive ILD
Methodological detailsconceptual framework, consensus threshold ≥75% agreement, each patient profile classified by at least four experts, 1-year follow-up data for progression
- Conceptual framework
- Consensus threshold ≥75% agreement
- Each patient profile classified by at least four experts
- 1-year follow-up data for progression
Recommendations
As reported in the abstract
Consensus achieved
Severity: consensus, 60 of 80 profiles
75%
Risk of progression: consensus, 57 of 80 profiles
71%
Progressive ILD: consensus, 24 of 40 profiles
60%
Further findings
Classification of profiles achieving consensus
- Clinical ILD
- 92%
- Low risk
- 54%
- Stable
- 71%
Items most influential in classification
- Severity and progression: FVC, extent of lung involvement on high resolution chest CT (HRCT)
- Risk of progression: primarily disease duration
Original publication
Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease. Rheumatology (Oxford). Published 29 September 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →